Brown Capital Management LLC Has $61.40 Million Holdings in Vericel Corporation $VCEL

Brown Capital Management LLC trimmed its holdings in Vericel Corporation (NASDAQ:VCEL) by 30.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,950,989 shares of the biotechnology company’s stock after selling 861,020 shares during the period. Vericel accounts for 2.5% of Brown Capital Management LLC’s holdings, making the stock its 16th largest position. Brown Capital Management LLC owned 3.87% of Vericel worth $61,398,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Conestoga Capital Advisors LLC raised its holdings in Vericel by 19.5% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 2,463,590 shares of the biotechnology company’s stock valued at $104,826,000 after acquiring an additional 401,990 shares in the last quarter. Geneva Capital Management LLC increased its position in shares of Vericel by 30.7% in the second quarter. Geneva Capital Management LLC now owns 1,784,927 shares of the biotechnology company’s stock worth $75,949,000 after purchasing an additional 419,183 shares during the period. Geode Capital Management LLC raised its stake in Vericel by 3.2% in the second quarter. Geode Capital Management LLC now owns 1,240,389 shares of the biotechnology company’s stock valued at $52,786,000 after purchasing an additional 38,799 shares in the last quarter. Champlain Investment Partners LLC lifted its position in Vericel by 62.5% during the second quarter. Champlain Investment Partners LLC now owns 997,291 shares of the biotechnology company’s stock worth $42,435,000 after purchasing an additional 383,498 shares during the period. Finally, New York State Common Retirement Fund grew its stake in Vericel by 3.3% during the second quarter. New York State Common Retirement Fund now owns 890,509 shares of the biotechnology company’s stock worth $37,891,000 after buying an additional 28,178 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on VCEL shares. Weiss Ratings restated a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Truist Financial decreased their price target on Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Finally, Zacks Research cut Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $57.50.

Vericel Stock Up 2.7%

NASDAQ VCEL opened at $36.94 on Tuesday. Vericel Corporation has a twelve month low of $29.24 and a twelve month high of $63.00. The company has a market cap of $1.87 billion, a price-to-earnings ratio of 153.92 and a beta of 1.24. The business’s fifty day moving average is $37.58 and its 200 day moving average is $36.26.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, November 6th. The biotechnology company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.12. The firm had revenue of $67.50 million during the quarter, compared to the consensus estimate of $64.57 million. Vericel had a return on equity of 4.30% and a net margin of 5.06%.The business’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period last year, the company earned ($0.02) earnings per share. On average, research analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Vericel Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.